-+ 0.00%
-+ 0.00%
-+ 0.00%
Samjin Pharmaceutical Says AR1001 Meets Phase 3 Goal in Alzheimer's Monotherapy Group
Share
Listen to the news
Samjin Pharmaceutical Says AR1001 Meets Phase 3 Goal in Alzheimer's Monotherapy Group
  • Samjin Pharmaceutical announced Phase 3 top-line results for early Alzheimer's treatment AR1001, received from Aribio on Nov. 17, 2026.
  • The trial met its primary objective through significant benefit in patients receiving AR1001 alone; results were not significant overall.
  • Serious adverse events were similar between groups, though treatment discontinuations due to adverse events were more frequent with AR1001.
  • Aribio independently conducted the global trial; Samjin holds exclusive production and sales rights in South Korea.
  • Plans call for discussions with the FDA and other regulators on further development and drug approval procedures.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Samjin Pharmaceutical Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261117800165), on November 17, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending